甲氧氯普胺对活动性上消化道出血患者内镜下胃部可视化的疗效:双盲随机对照试验
这项双盲、双中心随机对照试验纳入活动性上消化道出血患者,比较甲氧氯普胺与安慰剂对内镜下胃部可视化的效果。结果显示甲氧氯普胺未改善整体充分可视化率(77.4% vs 61.6%,OR 2.16,P=0.16),但降低了72小时内二次内镜需求(3.2% vs 22.6%,OR 0.11,P=0.02);在胃部病变亚组中改善了充分可视化率及胃底EVS评分。
要点
- 甲氧氯普胺未改善活动性上消化道出血患者的整体内镜充分可视化率。
- 甲氧氯普胺组72小时内二次内镜需求低于安慰剂组(3.2% vs 22.6%)。
- 胃部病变亚组中甲氧氯普胺改善充分可视化率及胃底EVS评分。
核心结论
- 甲氧氯普胺未改善整体活动性上消化道出血患者的内镜可视化,但降低了二次内镜需求。
- 在因胃部病变导致的上消化道出血患者中,甲氧氯普胺改善了胃部可视化,主要通过改善胃底可视化实现。
研究设计与样本
- 2021年4月10日至2022年10月8日开展的双盲、双中心随机对照试验,纳入活动性上消化道出血(呕血或鼻胃管见新鲜血液)患者。
- 合格患者按1:1隐藏分配至甲氧氯普胺组或安慰剂组。
- 68例合格患者中每组各3例因方案违背被排除,最终分析62例(甲氧氯普胺组31例,安慰剂组31例)。
主要发现
- 甲氧氯普胺组与安慰剂组充分可视化率分别为77.4%和61.6%(OR 2.16 [0.71-6.58],P=0.16)。
- 甲氧氯普胺组72小时内二次内镜需求低于安慰剂组(3.2% vs 22.6%,OR 0.11 [0.01-0.99],P=0.02)。
- 其他次要结局无差异。
- 胃部病变亚组分析中,甲氧氯普胺组充分可视化率高于对照组(92.9% vs 50%,OR 13 [1.32-128.10],P=0.03),胃底平均EVS评分也高于对照组(1.79 ± 0.42 vs 1.29 ± 0.72;P=0.03)。
关键数值与推荐
- 主要结局为采用客观内镜可视胃十二指肠评分(EVS)评估的充分可视化。
- 次要结局包括EVS平均差、食管胃十二指肠镜(EGD)时长、即刻止血、二次内镜需求、输血单位数、住院时长和30天再出血率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The 2021 American College of Gastroenterology Guidelines suggested using of intravenous erythromycin before endoscopy in patients with upper gastrointestinal bleeding (UGIB) to enhance endoscopic view and reduce the need for repeat endoscopy. Evidence on intravenous metoclopramide, which is more accessible, is scant, especially in patients with active UGIB. This study aimed to evaluate the efficacy of metoclopramide for gastric visualization in patients with active UGIB. METHODS: Between April 10, 2021, and October 8, 2022, this double-blind, double-center randomized controlled trial enrolled patients with active UGIB (hematemesis or presence of fresh blood in the nasogastric tube). The eligible patients were randomly assigned in a concealed 1:1 allocation to metoclopramide or placebo. The primary outcome was adequate visualization by objective endoscopic visualized gastroduodenal scores (EVS). Secondary outcomes included mean difference in EVS, duration of esophagogastroduodenoscopy (EGD), immediate hemostasis, need for a second look EGD, units of blood transfusion, length of hospital stay, and 30-day rebleeding rate. RESULTS: Of the 68 eligible patients, 3 of each group were excluded by protocol violation. Finally, 62 patients (31 metoclopramide and 31 placebo) were analyzed. The percentage of patients with adequate visualization in metoclopramide and placebo group was 77.4% and 61.6% (odds ratio [OR] 2.16 [0.71-6.58], P = 0.16). The need for a second look EGD in the 72 hours was lower in the metoclopramide group (3.2% vs 22.6%, OR 0.11 [0.01-0.99], P = 0.02), whereas the other secondary outcomes were not different. However, in gastric lesions subgroup analysis, metoclopramide improved the adequate visualization rate (92.9% vs 50%, OR 13 [1.32-128.10], P = 0.03) and mean EVS at fundus (1.79 ± 0.42 vs 1.29 ± 0.72; P = 0.03). DISCUSSION: Metoclopramide did not improve endoscopic visualization but decreased the need for second look EGD in patients with overall active UGIB. It improved gastric visualization in those with UGIB due to gastric lesions, primarily by improving visualization in the fundus ( ClinicalTrials.gov number NCT04771481).
引用
- Vimonsuntirungsri T, Thungsuk R, Nopjaroonsri P, et al. The Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Active Upper Gastrointestinal Bleeding: Double-Blind Randomized Controlled Trial. Am J Gastroenterol. 2023. PMID: 38059896. doi:10.14309/ajg.0000000000002620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。